ARTICLE | Clinical News
AZN to continue Cerovive Phase IIIs
October 14, 2004 7:00 AM UTC
Renovis (RNVS) partner AstraZeneca (LSE:AZN; AZN) will continue two international, double-blind Phase III trials of neuroprotectant Cerovive (NXY-059) based on a recommendation from an independent dat...